DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyunseung | ko |
dc.contributor.author | Kim, Soo Jung | ko |
dc.contributor.author | Jung, Kyung Hee | ko |
dc.contributor.author | Son, Mi Kwon | ko |
dc.contributor.author | Yan, Hong Hua | ko |
dc.contributor.author | Hong, Sungwoo | ko |
dc.contributor.author | Hong, Soon-Sun | ko |
dc.date.accessioned | 2014-12-09T06:14:19Z | - |
dc.date.available | 2014-12-09T06:14:19Z | - |
dc.date.created | 2013-08-26 | - |
dc.date.created | 2013-08-26 | - |
dc.date.issued | 2013-08 | - |
dc.identifier.citation | ONCOLOGY REPORTS, v.30, no.2, pp.863 - 869 | - |
dc.identifier.issn | 1021-335X | - |
dc.identifier.uri | http://hdl.handle.net/10203/192559 | - |
dc.description.abstract | Lung cancer is the leading cause of cancer-related mortality in the world, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases. Since more than 60% of NSCLC cases express the epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitors are used to treat NSCLC. However, due to the acquired resistance associated with EGFR-targeted therapy, other strategies for the treatment of NSCLC are urgently needed. Therefore, we investigated the anticancer effects of a novel phosphatidylinositol 3-kinase alpha (PI3K alpha) inhibitor, HS-173, in human NSCLC cell lines. HS-173 demonstrated anti-proliferative effects in NSCLC cells and effectively inhibited the PI3K signaling pathway in a dose-dependent manner. In addition, it induced cell cycle arrest at G(2)/M phase as well as apoptosis. Taken together, our results demonstrate that HS-173 exhibits anticancer activities, including the induction of apoptosis, by blocking the PI3K/Akt/mTOR pathway in human NSCLC cell lines. We, therefore, suggest that this novel drug could potentially be used for targeted NSCLC therapy. | - |
dc.language | English | - |
dc.publisher | SPANDIDOS PUBL LTD | - |
dc.subject | PHOSPHOINOSITIDE 3-KINASE PATHWAY | - |
dc.subject | ANTITUMOR-ACTIVITY | - |
dc.subject | ACQUIRED-RESISTANCE | - |
dc.subject | ERLOTINIB | - |
dc.subject | AKT | - |
dc.subject | GEFITINIB | - |
dc.subject | ARREST | - |
dc.subject | KINASE | - |
dc.subject | MUTATIONS | - |
dc.subject | APOPTOSIS | - |
dc.title | A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells | - |
dc.type | Article | - |
dc.identifier.wosid | 000321937600042 | - |
dc.identifier.scopusid | 2-s2.0-84879677951 | - |
dc.type.rims | ART | - |
dc.citation.volume | 30 | - |
dc.citation.issue | 2 | - |
dc.citation.beginningpage | 863 | - |
dc.citation.endingpage | 869 | - |
dc.citation.publicationname | ONCOLOGY REPORTS | - |
dc.identifier.doi | 10.3892/or.2013.2499 | - |
dc.contributor.localauthor | Hong, Sungwoo | - |
dc.contributor.nonIdAuthor | Lee, Hyunseung | - |
dc.contributor.nonIdAuthor | Kim, Soo Jung | - |
dc.contributor.nonIdAuthor | Jung, Kyung Hee | - |
dc.contributor.nonIdAuthor | Son, Mi Kwon | - |
dc.contributor.nonIdAuthor | Yan, Hong Hua | - |
dc.contributor.nonIdAuthor | Hong, Soon-Sun | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | HS-173 | - |
dc.subject.keywordAuthor | phosphatidylinositol 3-kinase inhibitor | - |
dc.subject.keywordAuthor | anticancer drug | - |
dc.subject.keywordAuthor | apoptosis | - |
dc.subject.keywordAuthor | non-small cell lung cancer | - |
dc.subject.keywordPlus | PHOSPHOINOSITIDE 3-KINASE PATHWAY | - |
dc.subject.keywordPlus | ANTITUMOR-ACTIVITY | - |
dc.subject.keywordPlus | ACQUIRED-RESISTANCE | - |
dc.subject.keywordPlus | ERLOTINIB | - |
dc.subject.keywordPlus | AKT | - |
dc.subject.keywordPlus | GEFITINIB | - |
dc.subject.keywordPlus | ARREST | - |
dc.subject.keywordPlus | KINASE | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | APOPTOSIS | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.